[노벨티노빌리티 상장 리부트]④ IPO 대비 C레벨 재편…기능별 삼각축

Novelligence is restructuring its executive leadership by separating technical, clinical, and financial functions to strengthen operational capacity ahead of its IPO. The company aims to simultaneously advance technology transfer deals, conduct clinical trials, and respond to capital market requirements through specialized C-level roles. This reorganization demonstrates that the biotech company is building the organizational infrastructure necessary to validate its antibody pipeline and secure investor confidence.